Company BeiGene, Ltd.

Equities

ONC

US07725L1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-04-24 pm EDT			5-day change	1st Jan Change
256.16 ^USD	+2.82%		+10.90%	+38.68%

Apr. 17	Nference and BeiGene Collaborate to Drive New B-Cell Cancer Research	CI
Apr. 11	Sector Update: Health Care Stocks Rise in Late Afternoon Trading	MT

Business description: BeiGene, Ltd.

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Number of employees: 11,000

Sales by Activity: BeiGene, Ltd.

Fiscal Period: December	2020	2021	2022	2023	2024
Pharmaceutical Products	309M	1.18B	1.42B	2.46B	3.81B

See all business segments

Geographical breakdown of sales: BeiGene, Ltd.

Fiscal Period: December	2020	2021	2022	2023	2024
United States (U.S)	18.23M	495M	503M	1.13B	1.96B
China	291M	517M	840M	1.1B	1.41B
Europe	-	-	-	202M	363M
Rest of World	-	164M	73.26M	26.6M	78.81M

See all geographic segments

Executive Committee: BeiGene, Ltd.

Manager	Title	Age	Since
John Oyler CEO	Chief Executive Officer	56	2010-10-27
Xiao Bin Wu PSD	President	63	2018-03-31
Aaron Rosenberg DFI	Director of Finance/CFO	49	2024-07-21
Yang Ji CMP	Compliance Officer	-	2017-08-31
Christiane Langer CTO	Chief Tech/Sci/R&D Officer	-	2021-07-31

See BEIGENE, LTD. governance

Composition of the Board of Directors: BeiGene, Ltd.

Director	Title	Age	Since
John Oyler CHM	Chairman	56	2016-01-26
Michael Goller BRD	Director/Board Member	50	2015-03-31
Ranjeev Krishana BRD	Director/Board Member	51	2014-09-30
Qing Qing Yi BRD	Director/Board Member	53	2014-09-30
Xiao Dong Wang CHM	Chairman	61	2010-10-27
Anthony Hooper BRD	Director/Board Member	70	2019-12-31
Corazon Sanders BRD	Director/Board Member	68	2020-08-23
Alessandro Riva BRD	Director/Board Member	64	2022-01-31
Margaret Dugan BRD	Director/Board Member	68	2022-01-31
Olivier Brandicourt BRD	Director/Board Member	69	2024-01-21

Composition of the Board of Directors

Shareholders: BeiGene, Ltd.

Name	Equities	%	Valuation
Baker Bros. Advisors LP 9.659 %	9,531,880	9.659 %	2 594 M $
Baker Bros. Advisors LP 8.927 %	8,809,471	8.927 %	2 398 M $
Capital Research & Management Co. (International Investors) 6.195 %	6,113,165	6.195 %	1 664 M $
PRIMECAP Management Co. 5.167 %	5,098,904	5.167 %	1 388 M $
HHLR Advisors Ltd. (Cayman Islands) 3.855 %	3,804,406	3.855 %	1 035 M $

Name	Equities	%	Valuation
AMGEN INC. 19.2 %	246,269,426	19.2 %	5 261 M $
HHLR Advisors Ltd. 6.186 %	79,357,423	6.186 %	1 695 M $
John Oyler 5.723 %	73,419,269	5.723 %	1 568 M $
Capital Research & Management Co. (International Investors) 5.696 %	73,078,400	5.696 %	1 561 M $
Xiao Dong Wang 1.277 %	16,381,727	1.277 %	350 M $

Name	Equities	%	Valuation
Penghua Fund Management Co., Ltd. 4.844 %	5,573,841	4.844 %	184 M $
ICBC Credit Suisse Asset Management Co., Ltd. 3.901 %	4,488,733	3.901 %	148 M $
Wanjia Asset Management Co., Ltd. 2.501 %	2,877,855	2.501 %	95 M $
Yinhua Fund Management Co., Ltd. 1.829 %	2,103,864	1.829 %	69 M $
Zhong Ou Asset Management Co., Ltd 1.719 %	1,977,895	1.719 %	65 M $

List of BEIGENE, LTD. shareholders

Holdings: BeiGene, Ltd.

Name	Equities	%	Valuation
LEAP THERAPEUTICS, INC. 3.17%	1,215,306	3.17%	370,668 $

Company details: BeiGene, Ltd.

BeiGene Ltd.

94 Solaris Avenue Camana Bay

KY1-1108, George Town

+345-949-4123

http://www.beigene.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BEIGENE, LTD.	+2.82%	+10.90%	+77.74%	+56.40%	26.9B
REGENERON PHARMACEUTICALS, INC.	+2.03%	+6.50%	-33.84%	-12.84%	62.91B
ARGENX SE	+0.76%	+1.41%	+51.93%	+81.31%	36.62B
BIONTECH SE	+4.97%	+22.05%	+36.84%	-16.91%	27.56B
SUMMIT THERAPEUTICS INC.	+10.44%	+49.13%	+922.28%	+1,744.22%	24.51B
WUXI APPTEC CO., LTD.	+0.36%	+7.45%	+34.46%	-44.47%	22.17B
INSMED INCORPORATED	-2.60%	-5.08%	+167.18%	+202.32%	12.87B
GENMAB A/S	+0.75%	+3.76%	-32.05%	-47.22%	12.69B
WUXI BIOLOGICS (CAYMAN) INC.	+0.22%	+6.03%	+79.36%	-57.41%	11.84B
AKESO, INC.	+1.70%	+15.38%	+110.53%	+698.12%	10.75B
Average	+2.15%	+11.28%	+141.44%	+260.35%	24.88B
Weighted average by Cap.	+2.53%	+11.29%	+121.07%	+216.30%